PARIS--(BUSINESS WIRE)--Regulatory News:

巴黎——（商业新闻短讯）——监管新闻：

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics, today announced the acquisition of Emglev Therapeutics, a spinoff of Institut Curie, one of France's leading cancer centers.

Valerio Therapeutics.A.（Euronext Growth Paris:ALVIO）是一家临床阶段生物技术公司，在创新DNA诱饵疗法的开发方面处于领先地位，今天宣布收购Emglev Therapeutics，这是法国领先的癌症中心之一居里研究所的一个分支。

Valour Bio has been established as a wholly owned subsidiary of Valerio Therapeutics to focus on discovering single domain antibodies (sdAbs) as drug and radio conjugates, bispecific T-cell engagers, blocking and binding sdAbs, or CAR-T sdAb drug candidates for multiple therapeutic areas.

Valour Bio是Valerio Therapeutics的全资子公司，专注于发现单结构域抗体（sdAb）作为药物和放射偶联物，双特异性T细胞参与者，阻断和结合sdAb或CAR-T sdAb候选药物用于多个治疗领域。

Emglev’s proprietary synthetic sdAb libraries overcome the current barriers of conventional antibody discovery by providing unique targets and selecting humanized or fully human sdAbs entirely in vitro. These sdAbs are validated for a wide array of therapeutic applications, offering a distinct advantage in antibody development..

Emglev专有的合成sdAb文库通过提供独特的靶标并完全在体外选择人源化或完全人源化的sdAb，克服了传统抗体发现的当前障碍。这些sdAb经过广泛的治疗应用验证，在抗体开发中具有明显的优势。。

Animal free sdAb screening strategies exploit highly diverse synthetic libraries and functional screening, enabling the identification of validated lead binders in less than two months. Since Emglev’s antibody scaffold is already humanized or derived from human variable region of the heavy chain (VH), there is no need for further humanization, thereby streamlining the development process and reducing the risk of immunogenicity and loss of affinity..

无动物sdAb筛选策略利用高度多样化的合成文库和功能筛选，能够在不到两个月的时间内鉴定出经过验证的铅结合剂。由于Emglev的抗体支架已经人源化或源自重链（VH）的人类可变区，因此无需进一步人源化，从而简化了开发过程并降低了免疫原性和亲和力丧失的风险。。

Emglev’s sdAb technology has broad applications in several therapeutic areas such as inflammatory disorders, autoimmune diseases and cancer, but it also allows for the development of various treatment modalities including sdAb drug and radio-conjugates, bispecific T-cell engagers, blocking and binding sdAb or CAR-T sdAb drugs to name a few.

Emglev的sdAb技术在炎症性疾病，自身免疫性疾病和癌症等多个治疗领域有着广泛的应用，但它也允许开发各种治疗方式，包括sdAb药物和放射偶联物，双特异性T细胞参与者，阻断和结合sdAb或CAR-T sdAb药物等等。

Pre-clinical proof-of-concept of the sdAb technology has been obtained using CAR-T sdAb, BiTE sdAb and sdAb-drug conjugate, highlighting the ability of Emglev to rapidly and efficiently discover tailored antibody fragments with enhanced properties. Added to the expertise brought by Valerio Therapeutics, this positions Valour Bio with a versatile and promising platform for developing new best-in-class or first-in-class therapies for a wide range of diseases..

已经使用CAR-T sdAb，BiTE sdAb和sdAb药物缀合物获得了sdAb技术的临床前概念验证，突出了Emglev快速有效地发现具有增强特性的定制抗体片段的能力。再加上Valerio Therapeutics带来的专业知识，这使Valour Bio成为一个多功能且有前途的平台，用于开发针对多种疾病的新型一流或一流疗法。。

The acquisition is structured through a sale of shares paid in cash and a contribution in kind of Emglev shares against Valour Bio shares. As a result, shareholders of Emglev became shareholders of Valour Bio.

此次收购是通过出售以现金支付的股票和以Emglev股票实物出资对抗Valour Bio股票的方式进行的。因此，Emglev的股东成为Valour Bio的股东。

Dr. Shefali Agarwal, President & Chief Executive Officer of Valerio Therapeutics and CEO of Valour Bio, stated:

Valerio Therapeutics总裁兼首席执行官兼Valour Bio首席执行官Shefali Agarwal博士表示：

“The acquisition of Emglev Therapeutics through our newly formed subsidiary Valour Bio reinforces our commitment to bring innovative therapeutics to patients. We are excited to advance this next-generation technology developed by the accomplished scientists at Emglev and we look forward to the novel treatments this platform may yield like sdAb drug and radio -conjugates, bispecific T-cell engagers, blocking and binding sdAb or CAR-T sdAb drugs.

“通过我们新成立的子公司Valour Bio收购Emglev Therapeutics，加强了我们为患者带来创新疗法的承诺。我们很高兴推进Emglev的杰出科学家开发的这项下一代技术，我们期待着该平台可能产生的新疗法，如sdAb药物和放射性结合物，双特异性T细胞参与者，阻断和结合sdAb或CAR-T sdAb药物。

Furthermore, we believe that the versatility of this platform can not only target a wide array of antigens but potentially address current limitations of antibody-based therapeutics such as tissue penetration, immunogenicity and ease of manufacturing. Following this acquisition, Valour Bio will focus on optimizing the therapeutic use of single-domain antibodies, focusing on developing treatments for severe and life-threatening diseases, including but not limited to autoimmune and inflammatory diseases as well as cancers.”.

此外，我们认为，该平台的多功能性不仅可以针对多种抗原，还可以解决基于抗体的治疗方法目前的局限性，例如组织渗透性，免疫原性和易于制造。收购后，Valour Bio将专注于优化单域抗体的治疗用途，重点开发严重和危及生命的疾病的治疗方法，包括但不限于自身免疫性和炎症性疾病以及癌症。”。

Christelle Masdeu, CEO of Emglev Therapeutics, commented:

Emglev Therapeutics首席执行官Christelle Masdeu评论道：

“We are excited to enter into this joint effort with Valerio Therapeutics. As a shareholder of Valour Bio now holding the Emglev platform, we remain committed to investing our energy, expertise and passion to develop unique treatments addressing unmet medical needs. The synergy created by combining Emglev’s proprietary synthetic single-domain antibody platform with Valerio’s distinctive preclinical and clinical development expertise perfectly aligns with our mission to deliver transformative therapies that make a meaningful difference in patients' lives.”.

“我们很高兴与Valerio Therapeutics共同努力。作为Valour Bio的股东，现在拥有Emglev平台，我们仍然致力于投入我们的精力、专业知识和热情来开发独特的治疗方法，以满足未满足的医疗需求。将Emglev专有的合成单域抗体平台与Valerio独特的临床前和临床开发专业知识相结合，所产生的协同作用与我们提供变革性治疗的使命完全一致，从而为患者的生活带来有意义的改变。”。

Dr. Sandrine Moutel, Emglev’s co-founder and head of the Antibody facility at Institut Curie and Dr. Franck Perez, Emglev’s co-founder and a member of its scientific board, director of the Cell Biology and Cancer Unit at Institut Curie, stated jointly:

Emglev的联合创始人兼居里研究所抗体设施负责人Sandrine Moutel博士和Emglev的联合创始人兼科学委员会成员、居里研究所细胞生物学和癌症部门主任Franck Perez博士共同表示：

“As founding members of Emglev, we are delighted to enter into this agreement which represents the culmination of tireless work by a dedicated team of scientists. Our team has created a platform that can generate therapeutics including CAR-Ts, T-cell engagers, binders, and bispecifics sdAbs demonstrating wide and versatile applicability to many diseases.

“作为Emglev的创始成员，我们很高兴签署这项协议，这代表了一支专门的科学家团队不懈努力的成果。我们的团队创建了一个平台，可以产生治疗药物，包括CAR-Ts，T细胞参与者，粘合剂和双特异性SDAb，证明了对许多疾病的广泛和多功能的适用性。

This new chapter allows us to bring our vision of single-domain antibodies one step closer to the clinic and we are looking forward to beginning this journey with Valerio Therapeutics.”.

这一新的篇章使我们能够将单域抗体的愿景更接近临床，我们期待着用Valerio Therapeutics开始这一旅程。”。

Cécile Campagne, Director of Institut Curie’s Technology Transfer Office, declared:

居里研究所技术转让办公室主任Cécile Campagne宣布：

“We are proud of the path taken by Emglev Therapeutics, a start-up that has emerged from Institut Curie's incubation program, which is moving forward at full speed! The acquisition of Emglev, less than two years after its creation, by Valour Bio, a subsidiary of Valerio Therapeutics which is a listed company, reflects the quality of Institut Curie’s innovations and the importance of putting them at the service of the creation of companies that will bring these cutting-edge technologies to all patients.”.

“我们为Emglev Therapeutics所走的道路感到骄傲，这是一家从居里研究所孵化计划中诞生的初创公司，该计划正在全速前进！上市公司Valerio Therapeutics的子公司Valour Bio收购Emglev不到两年，这反映了居里研究所创新的质量，以及将这些创新服务于创建将这些尖端技术带给所有患者的公司的重要性。”。

To this end, Valerio Therapeutics will provide Valour Bio with services in terms of scientific know-how in drug development, company support and equipment against financial compensation.

为此，Valerio Therapeutics将为Valour Bio提供药物开发、公司支持和设备方面的科学技术服务，以应对经济补偿。

Given the potential of the technology and depth of the market potential, Valour Bio is confident that it will find the needed financial resources to support the company’s growth. The acquisition and operation of Emglev will enable new scientific and financial synergies to be created within the Valerio Group, with the first benefits for Valerio Therapeutics and Valour Bio expected to materialize in Q1 2025..

鉴于技术的潜力和市场潜力的深度，Valour Bio有信心找到所需的财务资源来支持公司的发展。Emglev的收购和运营将使Valerio集团内部产生新的科学和财务协同效应，Valerio Therapeutics和Valour Bio的首批收益预计将在2025年第一季度实现。。

About Valour Bio

关于Valour Bio

Valour Bio is a discovery stage biotechnology company established through acquisition of Emglev’s unique proprietary single-domain antibody platform in September 2024. Valour Bio was established as a subsidiary of Valerio Therapeutics.

Valour Bio是一家发现阶段的生物技术公司，于2024年9月收购了Emglev独特的专有单域抗体平台。Valour Bio是Valerio Therapeutics的子公司。

Through pioneering science, strategic partnerships, and an unwavering commitment to enhancing patient outcomes, we strive to deliver hope and advance healthcare for those who need it most.

通过开创性的科学，战略合作伙伴关系以及对提高患者预后的坚定承诺，我们努力为最需要的人带来希望并推进医疗保健。

For further information, please visit valourbio.com

欲了解更多信息，请访问valourbio.com

About Valerio Therapeutics

关于Valerio Therapeutics

Valerio Therapeutics is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners..

Valerio Therapeutics是一家临床阶段的生物技术公司，通过在备受追捧的DNA损伤反应（DDR）领域的独特作用机制，开发针对肿瘤DNA结合功能的创新肿瘤药物。该公司专注于将早期一流或破坏性化合物从转化研究带到临床概念验证，这是吸引潜在合作伙伴的创造价值的转折点。。

For further information, please visit valeriotx.com

欲了解更多信息，请访问valeriotx.com

About Emglev Therapeutics

关于Emglev Therapeutics

Emglev Therapeutics is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology.

Emglev Therapeutics是一家生物技术公司，成立于2023年，是居里研究所（Institut Curie）的附属机构，致力于发现和开发变革性免疫疗法，以解决肿瘤学中未满足的医疗需求。

By leveraging its unique proprietary platform, the Company unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. The Company is focused on the development the next level of immunotherapies for the benefit of all the patients with high unmet needs..

通过利用其独特的专有平台，该公司解开了传统抗体发现的当前障碍，以提供独特的靶标和在体外完全选择的sdAb，并针对任何靶标以任何形式验证用于治疗应用。该公司专注于开发下一层次的免疫疗法，以造福所有需求未得到满足的患者。。

For further information, please visit www.emglev-tx.com

Forward looking statements

前瞻性声明

This communication expressly or implicitly contains certain forward-looking statements concerning Valerio Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Valerio Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

本通信明示或暗示包含有关Valerio Therapeutics及其业务的某些前瞻性声明。此类报表涉及某些已知和未知的风险、不确定性和其他因素，这些因素可能导致Valerio Therapeutics的实际结果、财务状况、业绩或成就与此类前瞻性报表明示或暗示的任何未来结果、业绩或成绩存在重大差异。

Valerio Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Valerio Therapeutics to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s annual report or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (https://valeriotx.com/) and/or the AMF (www.amf-france.org)..

Valerio Therapeutics自即日起提供此通讯，不承诺因新信息、未来事件或其他原因而更新此处包含的任何前瞻性声明。有关可能导致Valerio Therapeutics的实际业绩、财务状况、业绩或成就与前瞻性报表中所载不同的风险和不确定性的讨论，请参阅公司最近的年度报告或任何其他定期财务报告以及任何其他新闻稿中描述的风险因素，这些风险因素可在公司集团的网站上免费获得(https://valeriotx.com/)和/或AMF（www.AMF-france.org）。。